JP2015180198A5 - - Google Patents

Download PDF

Info

Publication number
JP2015180198A5
JP2015180198A5 JP2015044097A JP2015044097A JP2015180198A5 JP 2015180198 A5 JP2015180198 A5 JP 2015180198A5 JP 2015044097 A JP2015044097 A JP 2015044097A JP 2015044097 A JP2015044097 A JP 2015044097A JP 2015180198 A5 JP2015180198 A5 JP 2015180198A5
Authority
JP
Japan
Prior art keywords
serine
serine racemase
barrier function
expression level
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015044097A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015180198A (ja
JP6854073B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2015044097A priority Critical patent/JP6854073B2/ja
Priority claimed from JP2015044097A external-priority patent/JP6854073B2/ja
Publication of JP2015180198A publication Critical patent/JP2015180198A/ja
Publication of JP2015180198A5 publication Critical patent/JP2015180198A5/ja
Priority to JP2019186327A priority patent/JP6934925B2/ja
Application granted granted Critical
Publication of JP6854073B2 publication Critical patent/JP6854073B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015044097A 2014-03-05 2015-03-05 表皮セリンラセマーゼ及び／又はｄ−セリン量を指標とした、皮膚のバリア機能亢進薬剤のスクリーニング方法並びに皮膚バリア機能評価方法 Active JP6854073B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2015044097A JP6854073B2 (ja) 2014-03-05 2015-03-05 表皮セリンラセマーゼ及び／又はｄ−セリン量を指標とした、皮膚のバリア機能亢進薬剤のスクリーニング方法並びに皮膚バリア機能評価方法
JP2019186327A JP6934925B2 (ja) 2014-03-05 2019-10-09 セリンラセマーゼ活性化剤、及び皮膚のバリア機能亢進剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014043073 2014-03-05
JP2014043073 2014-03-05
JP2015044097A JP6854073B2 (ja) 2014-03-05 2015-03-05 表皮セリンラセマーゼ及び／又はｄ−セリン量を指標とした、皮膚のバリア機能亢進薬剤のスクリーニング方法並びに皮膚バリア機能評価方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019186327A Division JP6934925B2 (ja) 2014-03-05 2019-10-09 セリンラセマーゼ活性化剤、及び皮膚のバリア機能亢進剤

Publications (3)

Publication Number Publication Date
JP2015180198A JP2015180198A (ja) 2015-10-15
JP2015180198A5 true JP2015180198A5 (https=) 2016-04-28
JP6854073B2 JP6854073B2 (ja) 2021-04-07

Family

ID=54328827

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015044097A Active JP6854073B2 (ja) 2014-03-05 2015-03-05 表皮セリンラセマーゼ及び／又はｄ−セリン量を指標とした、皮膚のバリア機能亢進薬剤のスクリーニング方法並びに皮膚バリア機能評価方法
JP2019186327A Active JP6934925B2 (ja) 2014-03-05 2019-10-09 セリンラセマーゼ活性化剤、及び皮膚のバリア機能亢進剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019186327A Active JP6934925B2 (ja) 2014-03-05 2019-10-09 セリンラセマーゼ活性化剤、及び皮膚のバリア機能亢進剤

Country Status (1)

Country Link
JP (2) JP6854073B2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018174286A1 (ja) * 2017-03-24 2018-09-27 味の素株式会社 角層機能改善剤
WO2020045364A1 (ja) * 2018-08-27 2020-03-05 株式会社 資生堂 乾癬を判定するための皮膚試料の分析方法及びシステム
JP7237689B2 (ja) * 2019-03-28 2023-03-13 株式会社ナリス化粧品 ストレスに起因する皮膚バリア機能改善剤のスクリーニング方法
JP2023056255A (ja) * 2021-10-07 2023-04-19 エスエス製薬株式会社 色素斑形成抑制剤、メラノソーム貪食亢進抑制剤及び表皮分化能改善剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4202638B2 (ja) * 2001-12-12 2008-12-24 丸善製薬株式会社 コラーゲン産生促進剤、エラスターゼ阻害剤、コラゲナーゼ阻害剤及び老化防止用皮膚化粧料
JP2005041861A (ja) * 2003-07-09 2005-02-17 Takeda Chem Ind Ltd 皮膚角層水分量低下抑制剤
KR20120041740A (ko) * 2009-09-14 2012-05-02 가부시키가이샤 시세이도 자외선 장해 경감 조성물

Similar Documents

Publication Publication Date Title
McGaw et al. Cytotoxicity of African medicinal plants against normal animal and human cells
PH12018550037A1 (en) Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof
WO2016046640A3 (en) Methods for predicting drug responsiveness
JP2015180198A5 (https=)
MX390884B (es) Método para la cuantificación de los miembros del filogrupo i y/o del filogrupo ii de faecalibacterium prausnitzii y el uso de los mismos como biomarcadores.
WO2018106020A3 (ko) 파킨슨병을 진단하기 위한 정보제공방법
MX2009001070A (es) Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma.
Bai et al. Oral microbiota-driven cell migration in carcinogenesis and metastasis
MY196578A (en) Method for Determining Stage of Periodontal Disease
RU2017122187A (ru) Клеточный способ определения эффективности дефибротида
Samarelli et al. Small molecules for the treatment of long-COVID-related vascular damage and abnormal blood clotting: a patent-based appraisal
López-González et al. Socioeconomic inequalities and age and gender differences in cardiovascular risk factors
Silva et al. Characterization of aspartic proteases from Paracoccidioides brasiliensis and their role in fungal thermo-dimorphism
CR20210551A (es) Método de monitoreo de las concentraciones de perácidos mediante medidas de conductividad y composición de perácidos
EP3848039A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING FABRY'S DISEASE, CONTAINING A TSP1 PROTEIN INHIBITOR AS ACTIVE INGREDIENT
Pakotiprapha et al. Bridging the Gap: Can COVID-19 Research Help Combat African Swine Fever?
JP2014208601A5 (https=)
WO2016178083A3 (en) Method for measuring tear constitutents in a tear sample
DE602005008710D1 (de) Verfahren zur untersuchung der aktivität von ionenkanälen
RU2012141281A (ru) Способ лабораторной оценки эффективности антибактериальной терапии
JP2016088926A5 (https=)
RU2017139718A (ru) Агент, индуцирующий клеточную гибель, для клеток, имеющих мутации гена braf, агент, подавляющий рост для таких клеток, и фармацевтическая композиция для терапии заболеваний, вызванных дефектом роста таких клеток
WO2018087416A3 (es) Método para determinar la actividad de enfermedades autoinmunes y kit
AL-Janabi Effects of hydroxyl alkaline compounds on dermatophytic cells
Melnikov et al. Integral approach to evaluation of the pathogenic activity of Trypanosoma cruzi clones as exemplified by the Mexican strain